title: [Should we treat all diabetic patients with aspirin in primary prevention?].
abstract: Patients with diabetes have a higher risk of atherothrombotic disease. These patients have up to 4-fold more coronary artery diseases compared with patients without diabetes. Aspirin is one of the most prescribed treatments in the prevention of cardiovascular diseases. This article focuses on the effect of aspirin in primary prevention with a summary of interventional studies including diabetic patients. The guidelines from different speciality societies, notably the American Diabetes Association, are positive. However, the results of these studies are not conclusive. Cautions recommendations are proposed.
authors: Service d'endocrinologie, diabétologie et nutrition, Hôpitaux universitaires de Genève, 1211 Genève 14. anne.righetti@hcuge.ch
authors: A
authors: A
authors: Righetti
authors: P
authors: P
authors: De Moerloose
authors: J
authors: J
authors: Philippe
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011322:Primary Prevention
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin